Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/20/?d=1Neue Studien: Europe PMCdeRisk of Mortality of People With Psoriasis and Psoriatic Arthritis in Taiwan: A Nationwide Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/risk-of-mortality-of-people-with-psoriasis-and-psoriatic-arthritis-in-taiwan-a-nationwide-cohort-study-r91/ObjectiveResidual confounding effects and disease severity are attributed to controversial results in studies of psoriatic disease (PsD) and mortality. We aimed to evaluate the risk of mortality in patients with incident PsD, compared to matched controls from the population.

Methods

We used the nationwide, population-based insurance claim datasets in Taiwan from 2010 to 2018. Incident cases of PsD were identified by International Classification of Diseases (ICD) codes. A nonexposed cohort was established through propensity score matching (PSM). Deaths were identified via the National Mortality Database. We evaluated the risk of all-cause mortality in PsD compared to the PSM nonexposed individuals using Cox regression. The mortality risk was evaluated in patients with more severe disease stratified by systemic therapy use and having psoriatic arthritis (PsA).

Results

There were 108,642 patients with incident PsD (40.2% women) and an equal number of PSM non-PsD individuals. Compared to the age- and sex-matched controls, there was a higher risk of mortality among patients with PsD (adjusted hazard ratio [aHR] 1.73, 95% CI 1.68-1.77, P < 0.001). After PSM, we found an attenuated but persistent higher risk of mortality in PsD compared to controls (aHR 1.20, 95% CI 1.16-1.24). There was a trend of higher mortality in patients exposed to biologic therapies, but not for PsA.

Conclusion

There was an increased risk of all-cause mortality in individuals with PsD compared to individuals without PsD before and after both PSM and adjustment for comorbidities. The risk of mortality was higher in patients with psoriasis but not in patients with PsA as compared to controls.

Weiterlesen

]]>91Mon, 16 Jun 2025 15:32:57 +0000Unravelling the gut-skin axis: the role of gut microbiota in pathogenesis and management of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/unravelling-the-gut-skin-axis-the-role-of-gut-microbiota-in-pathogenesis-and-management-of-psoriasis-r90/Weiterlesen

]]>90Mon, 16 Jun 2025 15:32:57 +0000Lobetyolin alleviates IMQ‑induced psoriasis‑like skin inflammation by maintaining the homeostasis of the skin and inhibiting the inflammatory cytokines in dendritic cells.https://www.psoriasis-news.de/articles.html/1_articles/lobetyolin-alleviates-imq%E2%80%91induced-psoriasis%E2%80%91like-skin-inflammation-by-maintaining-the-homeostasis-of-the-skin-and-inhibiting-the-inflammatory-cytokines-in-dendritic-cells-r89/Codonopsis pilosula, exhibits potent antioxidant and antitumor properties, yet its potential for treating psoriasis remains unexplored. In the present study, it was found that topical treatment with LBT significantly inhibits psoriasis in mice and maintains skin homeostasis during disease progression by regulating genes associated with keratinocyte proliferation and differentiation, enhancing the PPAR signaling pathway, and upregulating genes and metabolites involved in linoleic acid metabolism. Additionally, LBT suppressed gene expression linked to cytokine activity as well as the Il17, Tnf and MAPK signaling pathways in IMQ‑treated dendritic cells (DCs). These findings underscored LBT's efficacy in reducing IMQ‑induced psoriasis‑like skin inflammation by preserving skin homeostasis and inhibiting inflammatory cytokines in DCs. The present results suggested that topically applied LBT could serve as a promising drug candidate for psoriasis treatment or as an adjunct to biologic therapies to prevent disease relapse.

Weiterlesen

]]>89Mon, 16 Jun 2025 15:32:57 +0000Psoriasis unveiled: The cellular ballet, molecular symphony, and genetic puzzle.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-unveiled-the-cellular-ballet-molecular-symphony-and-genetic-puzzle-r88/Weiterlesen

]]>88Mon, 16 Jun 2025 15:32:57 +0000Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/disease-modification-in-psoriasis-through-early-il-17-inhibitor-intervention-a-retrospective-cohort-study-r87/BackgroundAlthough IL-17 inhibitors like Secukinumab and Ixekizumab have shown significant efficacy in psoriasis, the impact of early intervention with biologics to modify the disease course and achieve long-term remission remains unclear.

Objectives

To examine the potential of early intervention with IL-17 inhibitors for disease modification in psoriasis.

Methods

We conducted a multicenter retrospective cohort study on moderate-to-severe plaque psoriasis patients who received at least 4 weeks of treatment with Secukinumab or Ixekizumab between April 2019 and April 2023, taking the relapse rate one year after cessation of treatment as the primary endpoint.

Results

Among 400 patients who discontinued treatment after achieving PASI90, the median relapse time was 3.29 months(approximately 14 weeks). Of 141 patients who discontinued treatment after achieving PASI90 for over a year, 24 (88.89%) in the ultra-short disease duration(USDD, psoriasis duration ≤ 1 year) group and 33 (82.5%) in the short disease duration(SDD, psoriasis duration ≤ 2 year) group achieved one year of drug-free remission.

Limitations

The potential impact of early intervention on comorbidity development was not addressed in this study.

Conclusion

Early intervention with IL-17 inhibitors leads to faster responses and may promote disease modification in psoriasis.

Weiterlesen

]]>87Mon, 16 Jun 2025 15:32:57 +0000Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Reporthttps://www.psoriasis-news.de/articles.html/1_articles/deucravacitinib-treatment-for-psoriasis-complicated-by-myelodysplastic-syndrome-without-exacerbation-of-the-underlying-hematologic-disorder-a-case-report-r86/No abstract supplied.

Weiterlesen

]]>86Mon, 16 Jun 2025 15:32:57 +0000Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.https://www.psoriasis-news.de/articles.html/1_articles/patient-reported-outcomes-by-baseline-body-surface-area-involvement-among-individuals-initiating-biologic-therapy-results-from-the-corevitas-psoriasis-registry-r84/IntroductionPsoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy.

Methods

Patients from the CorEvitas Psoriasis Registry initiating biologics between April 2015 and September 2023 were categorized according to low (< 3%), medium (3-10%), or high (> 10%) BSA involvement. Measures assessed at initiation of biologic therapy included health-related quality of life, itch, pain, fatigue, psoriatic arthritis, psoriasis disease characteristics, and medical history. Overlap between BSA groups for each outcome was calculated via non-parametric Mann-Whitney statistic transformation (range 0.0-1.0; 0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]; 0 or 1 indicates complete dissimilarity) to determine whether each measure differed in randomly selected patients with low or medium versus high BSA.

Results

Of 1640 patients who initiated biologics, 7.0% had low BSA, 46.9% had medium BSA, and 46.2% had high BSA involvement. PRO overlap statistics ranged from 0.52 to 0.59 and from 0.60 to 0.70 for randomly selected patients with high versus medium and low BSA, respectively, indicating patients with high and medium BSA are likely to have similar levels of disease burden, and patients with high BSA are slightly more likely to have higher disease burden than those with low BSA. Near complete overlap (range 0.44-0.58) was observed for psoriasis disease characteristics and medical history in the low versus high and medium BSA groups.

Conclusion

Observed overlap in PROs across BSA categories shows that patients with low BSA can experience similarly poor quality of life and high symptom burden to those with higher BSA. These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden.

Trial registration

ClinicalTrials.gov: NCT02707341.

Weiterlesen

]]>84Sat, 14 Jun 2025 05:52:56 +0000Causal association between immune cytokines and psoriasis: A two-way Mendelian randomization study.https://www.psoriasis-news.de/articles.html/1_articles/causal-association-between-immune-cytokines-and-psoriasis-a-two-way-mendelian-randomization-study-r83/Weiterlesen

]]>83Sat, 14 Jun 2025 05:52:56 +0000Managing Scalp Psoriasis Through Ayurvedic Therapies: A Case Report.https://www.psoriasis-news.de/articles.html/1_articles/managing-scalp-psoriasis-through-ayurvedic-therapies-a-case-report-r82/BackgroundPsoriasis, a chronic inflammatory skin condition, poses significant management challenges due to its persistent nature, recurrences, and side effects associated with conventional therapies. Ayurveda correlates psoriasis with Ekakushtha (a type of skin disorder), primarily involving Vata-Kapha dosha imbalance.

Objective

To evaluate the efficacy of Ayurvedic therapies, including Shodhana (Vamana, Raktamokshana) and Shamana (pacification medications), in managing scalp psoriasis.

Methodology

A 35-year-old male with chronic scalp psoriasis underwent Panchakarma, including Vamana (therapeutic emesis). Post-Shodhana, conservative management included 777 oil, Psora soap, Panchatikta Ghrita Guggulu, and Sut Shekhar Ras, along with Leech therapy (Raktamokshana) weekly for one month. Lifestyle and dietary modifications were also advised.

Results

The patient experienced significant relief from itching, scaling, erythema, and lesion thickness. Follow-up revealed improved scalp texture, reduced scaling, and absence of flare-ups. No adverse effects were reported.

Conclusion

Ayurvedic interventions combining detoxification (Shodhana) and pacification (Shamana) therapies demonstrated a safe and effective approach for managing scalp psoriasis, addressing systemic pathology while minimizing side effects. Further clinical trials are warranted to validate these findings.

Keywords

Ayurvedic treatment, therapeutic emesis, Vaman, Panchatikta Ghrita, Leech Therapy, Psora soap, scalp psoriasis, case report.

Weiterlesen

]]>82Sat, 14 Jun 2025 05:52:56 +0000PIEZO1 promotes psoriasis-like skin inflammation in mice via NF-κB/IL-17 signaling pathway activation.https://www.psoriasis-news.de/articles.html/1_articles/piezo1-promotes-psoriasis-like-skin-inflammation-in-mice-via-nf-%CE%BAbil-17-signaling-pathway-activation-r81/No abstract supplied.

Weiterlesen

]]>81Sat, 14 Jun 2025 05:52:56 +0000Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden.https://www.psoriasis-news.de/articles.html/1_articles/comorbid-psoriasis-in-systemic-lupus-erythematosus-a-cohort-study-from-a-tertiary-referral-centre-and-the-national-patient-register-in-sweden-r80/ObjectivesTo investigate the prevalence of psoriasis in SLE using a Swedish regional cohort and a nationwide cohort from the National Patient Register (NPR). Furthermore, we compared clinical features between patients with and without comorbid psoriasis.

Methods

In total, 351 patients diagnosed with SLE based on the 1982 American College of Rheumatology and/or the 2012 Systemic Lupus International Collaborating Clinics criteria from Linköping University Hospital were evaluated. We obtained patient-reported and relevant clinical data extracted in 2024. Individuals with coexisting psoriasis were identified via the International Classification of Diseases code L40 and subsequent confirmation through chart review in the regional cohort. In the NPR, 7490 subjects with SLE living in Sweden in 2022 were identified, as well as therapies obtained from the Prescribed Drug Register.

Results

We identified 12 subjects with SLE and coexisting psoriasis (3.4%) in the regional cohort and 367 patients (4.9%) in the nationwide cohort. Men were proportionally more common in the group with comorbid psoriasis in both cohorts. Patients with psoriasis reported more pain on a visual analogue scale (median 45.5/100 mm, IQR 23.3-58.3) compared with those without coexisting psoriasis (median 27.0/100 mm, IQR 7.0-50.5, p<0.04). We observed no differences in damage accrual or clinical phenotypes between the two groups. Subjects with psoriasis were more frequently prescribed methotrexate in the nationwide cohort.

Conclusion

The prevalence of coexisting psoriasis in patients with SLE in Sweden was estimated to be 3.4-4.9%. Individuals with comorbid psoriasis reported more pain and were more likely to be prescribed methotrexate than those without psoriasis.

Weiterlesen

]]>80Sat, 14 Jun 2025 05:52:56 +0000"Full-naïve" patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis - a monocentric retrospective study.https://www.psoriasis-news.de/articles.html/1_articles/full-na%C3%AFve-patients-the-impact-of-previous-methotrexate-cyclosporine-and-acitretin-on-first-line-biologics-response-in-the-treatment-of-moderate-to-severe-psoriasis-a-monocentric-retrospective-study-r79/BackgroundThe impact of traditional systemic drugs to treat psoriasis (ciclosporin, methotrexate, and acitretin) in a subsequent response to biologics, has not been adequately addressed in the literature. In clinical practice it is increasingly necessary to initiate, due to concomitant comorbidities, biologics in patients with psoriasis or psoriatic arthritis (PsA) who have not undergone prior treatment with systemics, i.e. full-naive.

Objectives and methods

This study analyzed the possible impact of non-biological systemic therapies on the effectiveness and drug survival of first-line biologic drug up to 12 months in bio-naive psoriatic and PsA patients consecutively enrolled from January 2017 to March 2021.

Results

95 patients with severe psoriasis (13.5%) were full-naive. Being full-naive and having or not having undergone methotrexate or cyclosporine therapy did not impact response to subsequent years of biologic therapy. Only acitretin promotes faster response to subsequent biologic drugs with 59.6% and 74.2% of patients achieving Psoriasis Area Severity Index (PASI) 90 at 16 and 28 Week, respectively, vs. 50.5% and 65% (p = 0.034 and 0.026). In multivariate analysis, the advantage given by acitretin was lost.

Conclusion

Previous systemic therapy in bio-naive patients does not appear to result in a differential response to biologics during the first year of treatment.

Weiterlesen

]]>79Sat, 14 Jun 2025 05:52:56 +0000Gender differences in psychological features and determinates of quality of life in axial spondyloarthritis and psoriatic arthritis: a cross-sectional study.https://www.psoriasis-news.de/articles.html/1_articles/gender-differences-in-psychological-features-and-determinates-of-quality-of-life-in-axial-spondyloarthritis-and-psoriatic-arthritis-a-cross-sectional-study-r78/BackgroundInvestigating gender-specific differences in rheumatology is crucial for improving personalized treatment. The present study aimed to explore gender differences in psychological characteristics and features associated with impaired physical and mental quality of life in male and female patients affected by axial spondyloarthritis or psoriatic arthritis.

Methods

The present study is cross-sectional. Quality of life was evaluated using a Medical Outcome Study 36-item Short Form health survey (SF-36), and physical and mental component scores were presented. Data about disease activity, anxiety and depression, fatigue, perceived stress, and coping strategies were collected. The patients were stratified by gender, and clinical and psychological data were compared.

Results

A total of 119 patients with axial spondyloarthritis [age 49.0 (SD 11.7); 45.4% F] and 198 patients with psoriatic arthritis [age 56.9 (SD 11.6); 62.6% F] were included. Female patients with axial spondyloarthritis and psoriatic arthritis had worse scores on fatigue, pain, perceived stress, physical quality of life, dysfunctional coping strategies, mental quality of life (only in axial spondyloarthritis), and anxiety (only in psoriatic arthritis) than men. In multivariable analysis, physical quality of life is mainly explained by fatigue and pain, and mental quality of life by fatigue, anxiety and stress in women with axial spondyloarthritis and psoriatic arthritis. Fatigue, pain and anxiety were significant variables across the models with male patients.

Conclusions

The study indicates that female patients with axial spondyloarthritis and psoriatic arthritis experience worse scores in psychological variables compared to men. Additionally, women's quality of life is significantly lower when compared to men's one, primarily due to factors such as fatigue, stress, pain, and anxiety. To enhance patient well-being, therapeutic strategies should be tailored to address the unique clinical and psychological needs that arise from gender differences.

Weiterlesen

]]>78Sat, 14 Jun 2025 05:52:56 +0000Long-term air pollutants exposure on risk of psoriasis: the mediating role of accelerated biological aging among 284,544 participants.https://www.psoriasis-news.de/articles.html/1_articles/long-term-air-pollutants-exposure-on-risk-of-psoriasis-the-mediating-role-of-accelerated-biological-aging-among-284544-participants-r77/Weiterlesen

]]>77Sat, 14 Jun 2025 05:52:56 +0000The Association of Psoriasis and Bacterial Infections in Pediatric Patients: A Retrospective Review.https://www.psoriasis-news.de/articles.html/1_articles/the-association-of-psoriasis-and-bacterial-infections-in%C2%A0pediatric-patients-a-retrospective-review-r76/Background/objectivesGuttate psoriasis onset and plaque psoriasis flares are associated with streptococcal pharyngitis. Literature regarding the relationship between anogenital bacterial dermatitis and psoriasis in pediatric patients is limited. We aimed to evaluate the clinical characteristics, microbiology, and treatment course of patients with psoriasis/psoriasiform dermatitis and concomitant pharyngeal and/or anogenital bacterial infections.

Methods

A multicenter retrospective review of patients ≤ 18 years of age with psoriasis/psoriasiform dermatitis and bacterial infection, defined by positive culture results, was performed. Demographic characteristics, clinical features, microbiology, treatment recommendations, and outcomes were evaluated. Comparisons were made between pharyngeal and anogenital culture groups.

Results

A total of 166 unique patients with psoriasis/psoriasiform dermatitis and suspected pharyngeal and/or anogenital infection were evaluated between 2011 and 2021. Staphylococcus sp. and Streptococcus sp. were isolated in anogenital cultures. Inverse psoriasis was associated with a positive anogenital culture (p = 0.0356). Guttate psoriasis was more common in patients with a positive pharyngeal culture (p < 0.0001). Treatment of a positive bacterial culture did not correlate with the treatment response of psoriasis/psoriasiform dermatitis.

Conclusions

Investigations for anogenital and pharyngeal infections should be considered in pediatric patients presenting with new-onset or worsening psoriasis. A high clinical suspicion should be maintained for anogenital infection in patients with inverse psoriasis, specifically.

Weiterlesen

]]>76Sat, 14 Jun 2025 05:52:56 +0000Exploring the association between relative fat mass and psoriasis risk: insights from the NHANES data.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-association-between-relative-fat-mass-and-psoriasis-risk-insights-from-the-nhanes-data-r75/BackgroundPatients' quality of life is greatly impacted by psoriasis, a prevalent chronic inflammatory skin condition that is frequently linked to a number of systemic disorders. Recent research shows that obesity is a major risk factor for psoriasis. Since Relative Fat Mass (RFM), an innovative way to measure obesity, offers a more precise estimate of body fat percentage, this study aims to investigate the connection between RFM and psoriasis and its potential as a disease predictor.

Methods

The analysis included 6,006 people the National Health and Nutrition Examination Survey (NHANES) conducted between 2003 and 2006, 151 of whom had psoriasis. Weighted multivariable logistic regression, restricted cubic splines (RCS), subgroup analysis, and interaction tests were employed to assess the link between RFM and psoriasis. ROC curves were used to compare RFM with conventional measures of obesity (WWI, BRI). Furthermore, LASSO regression and multivariable regression based on AIC were used to create a psoriasis risk prediction model that included RFM and additional clinical factors.

Results

RFM and psoriasis risk were revealed to be significantly positively correlated. The chance of developing psoriasis increased by 7% for every unit rise in RFM (95% CI: 1.03 to 1.12). RFM showed better predictive ability than conventional markers including BMI, WWI, and BRI (AUC = 0.573). The RFM-psoriasis relationship and diabetes status significantly interacted, with the association being weaker in diabetic individuals, according to subgroup analysis and interaction tests. Promising results were obtained from the created psoriasis risk prediction model that included RFM, age, total dietary sugar, education level, history of heart disease, and hypertension.

Conclusion

This research demonstrates that RFM outperforms traditional anthropometric methods in predicting risk. It also presents the initial evidence establishing a positive link between RFM and the likelihood of developing psoriasis.The psoriasis risk prediction model underscores RFM's effectiveness as a valuable approach in both clinical and public health domains, aiming to alleviate the impact of psoriasis-related issues by offering a practical instrument for early risk assessment and personalized clinical strategies.

Weiterlesen

]]>75Sat, 14 Jun 2025 05:52:56 +0000Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cellshttps://www.psoriasis-news.de/articles.html/1_articles/effects-of-adalimumab-on-mitochondria-of-psoriatic-mesenchymal-stem-cells-r74/No abstract supplied.

Weiterlesen

]]>74Wed, 11 Jun 2025 06:56:28 +0000Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Surveyhttps://www.psoriasis-news.de/articles.html/1_articles/understanding-psoriasis-patient-preferences-for-biologic-dosing-frequencies-insights-from-a-patient-survey-r73/No abstract supplied.

Weiterlesen

]]>73Sat, 07 Jun 2025 16:48:48 +0000Are psoriasis severity and comorbidities associated with diet quality? A cross-sectional analysis using UK Biobank.https://www.psoriasis-news.de/articles.html/1_articles/are-psoriasis-severity-and-comorbidities-associated-with-diet-quality-a-cross-sectional-analysis-using-uk-biobank-r72/Weiterlesen

]]>72Thu, 05 Jun 2025 13:21:39 +0000Immunoglobulin A vasculitis and pustular psoriasis precipitated by Tawon Liar: a case report.https://www.psoriasis-news.de/articles.html/1_articles/immunoglobulin-a-vasculitis-and-pustular-psoriasis-precipitated-by-tawon-liar-a-case-report-r71/Weiterlesen

]]>71Thu, 05 Jun 2025 13:21:39 +0000Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies.https://www.psoriasis-news.de/articles.html/1_articles/effectiveness-of-tildrakizumab-200%C2%A0mg-in-moderate-to-severe-plaque-psoriasis-a-multicenter-real-world-study-analyzing-patient-outcomes-by-weight-pasi-bmi-and-previous-therapies-r70/IntroductionPsoriasis is a chronic immune-mediated disease with significant systemic implications. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in moderate-to-severe plaque psoriasis. Higher doses may be beneficial for patients with elevated body weight or greater disease burden. This study evaluates the effectiveness of tildrakizumab 200 mg in a real-world setting, analyzing outcomes based on weight, Psoriasis Area Severity Index (PASI), body mass index (BMI), and prior biologic exposure.

Methods

A multicenter retrospective study was conducted across 10 Italian hospitals. Adult patients (≥ 18 years) with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg for ≥ 36 weeks were included. Patients were stratified by weight (≥ 90 kg vs. < 90 kg), BMI (≥ 30 vs. < 30), PASI (≥ 15 vs. < 15), and biologic history (naïve vs. biologic (bio)-experienced). PASI100 response rates at 36 weeks were assessed. Statistical analyses included Fisher's exact test (p < 0.05 significant).

Results

Among 137 patients, PASI100 response rates were 67.1% for patients < 90 kg vs. 49.2% for ≥ 90 kg (p = 0.04), 61.5% for PASI < 15 vs. 50% for PASI ≥ 15 (p = 0.03), and 60.8% for bio-naïve vs. 57.1% for bio-experienced (p = 0.08). BMI ≥ 30 was associated with lower PASI100 (44.2%) compared to BMI < 30 (61.4%) (p = 0.05). Despite subgroup differences, all patients exhibited clinical improvement.

Conclusion

Tildrakizumab 200 mg effectively treated moderate-to-severe psoriasis across diverse patient subgroups. While higher weight and PASI were associated with slightly lower PASI100 rates, significant improvements were observed, supporting its role in difficult-to-treat patients.

Weiterlesen

]]>70Thu, 05 Jun 2025 13:21:39 +0000Multimodal Function of Mesenchymal Stem Cells in Psoriasis Treatment.https://www.psoriasis-news.de/articles.html/1_articles/multimodal-function-of-mesenchymal-stem-cells-in-psoriasis-treatment-r69/Weiterlesen

]]>69Thu, 05 Jun 2025 13:21:39 +0000Tratamiento tópico de la psoriasis: recomendaciones de expertos del Grupo Español de Psoriasis (GPS).https://www.psoriasis-news.de/articles.html/1_articles/tratamiento-t%C3%B3pico-de-la-psoriasis-recomendaciones-de-expertos-del-grupo-espa%C3%B1ol-de-psoriasis-gps-r68/Weiterlesen

]]>68Thu, 05 Jun 2025 13:21:39 +0000Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.https://www.psoriasis-news.de/articles.html/1_articles/deucravacitinib-in-patients-with-plaque-psoriasis-who-screened-positive-for-psoriatic-arthritis-improvements-in-joint-pain-and-the-impact-of-musculoskeletal-symptoms-r67/Weiterlesen

]]>67Thu, 05 Jun 2025 13:21:39 +0000Long term outcomes among patients with pre-existing psoriasis undergoing immune checkpoint inhibitor therapy: a case series and literature reviewhttps://www.psoriasis-news.de/articles.html/1_articles/long-term-outcomes-among-patients-with-pre-existing-psoriasis-undergoing-immune-checkpoint-inhibitor-therapy-a-case-series-and-literature-review-r66/Psoriasiform adverse cutaneous reactions to immune checkpoint inhibitor (ICI) therapy for cancer are potentially treatment-limiting. Few studies have investigated long-term outcomes related to exacerbations of pre-existing psoriasis and their impact on the efficacy of cancer treatment. Understanding outcomes in patients with autoimmune disease is important to guide management of these reactions and avoid unnecessary exclusion from ICI therapy. We conducted a retrospective cohort study using the University of Kansas Cancer Center database. We identified 20 adult patients with pre-existing psoriasis who were treated with ICIs between 2013 and 2022 and had at least one year of follow-up. Of these, 15 experienced exacerbation of their psoriasis during ICI therapy. Patients with exacerbation completed a higher median number of ICI cycles than those with unaffected psoriasis (16 vs. 9 cycles). Rates of ICI discontinuation due to side effects were similar between the two groups (26% vs. 20%). Kaplan-Meier analysis showed that patients with psoriasis exacerbation had significantly better progression-free survival compared to unaffected patients (p = 0.015). Although overall mortality was lower in the exacerbation group (40% vs. 60%), this difference was not statistically significant. Two patients with severe flares discontinued ICIs and initiated systemic therapy for psoriasis. One continued to show tumor remission, while the other maintained stable tumor burden, highlighting the variability and chronicity of flare responses. Overall, ICIs appear to be tolerable in patients with pre-existing psoriasis. Despite the high rate of exacerbation, most flares were mild and manageable with topical therapy, and most patients were able to complete their treatment. The comparable discontinuation rates and greater number of ICI cycles among those with flares suggest that psoriasis exacerbation does not necessarily impede cancer therapy. These findings support the inclusion of patients with psoriasis in ICI treatment protocols and suggest that cutaneous irAEs may be associated with improved therapeutic outcomes. Although limited by small sample size and retrospective design, this study contributes to the growing body of evidence supporting safe ICI use in patients with pre-existing autoimmune skin disease.

Weiterlesen

]]>66Thu, 05 Jun 2025 13:21:39 +0000